Epsilon M&A Deal Report - Horus Pharma
Transaction Multiples for the Valuation of Private Companies
Eurazeo / Horus Pharma
No EMAT :
109015
Announced Date :
14/03/2022
Type :
LBO (Leverage Buy Out)
Deal Value :
Yes
Acquirer :
Eurazeo
Target :
Horus Pharma
Country :
Alpes-Maritimes
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
- Food Producers > Food & Beverage Industry > Food Complements
Business Description :
Founded in 2003, Horus Pharma is an ophthalmology pharmaceuticals producer in France . > Sells a wide range of more than 40 medicines, medical devices and food supplements designed to facilitate eye...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|
|
|
|
|
| Current |
Rating :
***
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 128
- Number of EMAT Reports / sub-sector « Food Complements » = 116
| Date | Acquirer | Target | Country | Multiples | See details |
| 28/02/2022 | Funding round led SWEN Capital Partners, BNP Paribas Développement | Entomojo (Tomojo) | Paris | ** | 108825 |
| 02/03/2020 | Funding round led by business angels | Laboratoire pour la Santé Animale (LAPSA) | Hauts-De-Seine | * | 108819 |
Source: Epsilon Research / EMAT
